Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 7047238, 7 pages
http://dx.doi.org/10.1155/2016/7047238
Review Article

Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease

1Department of Physiology, University Health Sciences Centre (Centro Universitario de Ciencias de la Salud), University of Guadalajara, 44150 Guadalajara, JAL, Mexico
2Nephrology Service, Civil Hospital of Guadalajara “Dr. Juan I. Menchaca”, Guadalajara, JAL, Mexico

Received 6 April 2016; Accepted 9 May 2016

Academic Editor: Konstantinos Papatheodorou

Copyright © 2016 Alejandra Guillermina Miranda-Díaz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Vallon and S. C. Thomson, “Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney,” Annual Review of Physiology, vol. 74, pp. 351–375, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. F. N. Ziyadeh, B. B. Hoffman, D. C. Han et al., “Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 14, pp. 8015–8020, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. F. M.-M. Lai, C.-C. Szeto, P. C. L. Choi et al., “Isolate diffuse thickening of glomerular capillary basement membrane: a renal lesion in prediabetes?” Modern Pathology, vol. 17, no. 12, pp. 1506–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Almualm and H. Zaman Huri, “Chronic kidney disease screening methods and its implication for Malaysia: an in depth review,” Global Journal of Health Science, vol. 7, no. 4, pp. 96–109, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. “Summary of recommendation statements,” Kidney International Supplements, vol. 3, no. 1, pp. 5–14, 2013.
  7. J. C. Longenecker, J. Coresh, M. J. Klag et al., “Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD,” Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 520–529, 2000. View at Google Scholar · View at Scopus
  8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, “KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease,” Kidney International, vol. 3, supplement 3, pp. 1–150, 2012. View at Google Scholar
  9. A. M. Cueto-Manzano, L. Cortes-Sanabria, H. R. Martinez-Ramirez et al., “Detection of early nephropathy in Mexican patients with type 2 diabetes mellitus,” Kidney International, vol. 68, no. 97, pp. S40–S45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. National Kidney Foundation, “KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update,” American Journal of Kidney Diseases, vol. 60, no. 5, pp. 850–886, 2012. View at Publisher · View at Google Scholar
  11. R. Friedman and J. L. Gross, “Evolution of glomerular filtration rate in proteinuric NIDDM patients,” Diabetes Care, vol. 14, no. 5, pp. 355–359, 1991. View at Google Scholar · View at Scopus
  12. G. T. Obrador, G. García-García, A. R. Villa et al., “Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) México and comparison with KEEP US,” Kidney International. Supplement, no. 116, pp. S2–S8, 2010. View at Google Scholar · View at Scopus
  13. R. Alcazar-Arroyo, L. Orte-Martinez, and A. Otero-Gonzalez, “Estudio de estrés oxidativo en Enfermedad Renal Crónica Avanzada,” Nefrologia, supplement 3, pp. 3–6, 2008. View at Google Scholar
  14. M. J. Puchades Montesa, M. A. González Rico, M. A. Solís Salguero et al., “Estudio del estrés oxidativo en enfermedad renal crónica avanzada,” Nefrologia, vol. 29, no. 5, pp. 464–473, 2009. View at Google Scholar
  15. M. E. Molitch, R. A. DeFronzo, M. J. Franz et al., “Nephropathy in diabetes,” Diabetes Care, vol. 27, no. 1, pp. S79–S83, 2004. View at Google Scholar
  16. P. E. Stevens and A. Levin, “Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline,” Annals of Internal Medicine, vol. 158, no. 11, pp. 825–830, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Radbill, B. Murphy, and D. LeRoith, “Rationale and strategies for early detection and management of diabetic kidney disease,” Mayo Clinic Proceedings, vol. 83, no. 12, pp. 1373–1381, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. N. Van Buren and R. Toto, “Current update in the management of diabetic nephropathy,” Current Diabetes Reviews, vol. 9, no. 1, pp. 62–77, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Gonzalez Villalpando, M. P. Stern, B. Arredondo Perez et al., “Nephropathy in low income diabetics: the Mexico City Diabetes Study,” Archives of Medical Research, vol. 27, no. 3, pp. 367–372, 1996. View at Google Scholar · View at Scopus
  20. A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull, and R. R. Holman, “Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64),” Kidney International, vol. 63, no. 1, pp. 225–232, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. J. L. Gross, M. J. De Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz, “Diabetic nephropathy: diagnosis, prevention, and treatment,” Diabetes Care, vol. 28, no. 1, pp. 164–176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Montañés Bermúdez, S. Gracia García, D. Pérez Surribas, A. Martínez Castelao, and J. Bover Sanjuán, “Documento de Consenso. Recomendaciones sobre la valoración de la proteinuria en el diagnóstico y seguimiento de la enfermedad renal crónica,” Nefrologia, vol. 31, no. 3, pp. 331–345, 2011. View at Google Scholar
  23. N. Montero, M. J. Soler, M. J. Pascual et al., “Correlación entre el cociente proteína/creatinina en orina esporádica y las proteínas en orina de 24 horas,” Nefrologia, vol. 32, no. 4, pp. 494–501, 2012. View at Google Scholar
  24. E. Ritz, “Diabetic nephropathy,” Saudi Journal of Kidney Diseases and Transplantation, vol. 17, no. 4, pp. 481–490, 2006. View at Google Scholar · View at Scopus
  25. S. Dronavalli, I. Duka, and G. L. Bakris, “The pathogenesis of diabetic nephropathy,” Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 8, pp. 444–452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. C. K. Kramer, C. B. Leitão, L. C. Pinto, S. P. Silveiro, J. L. Gross, and L. H. Canani, “Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria,” Diabetes Care, vol. 30, no. 8, pp. 1998–2000, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Balakumar, M. K. Arora, J. Reddy, and M. B. Anand-Srivastava, “Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism,” Journal of Cardiovascular Pharmacology, vol. 54, no. 2, pp. 129–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. L. Caramori, P. Fioretto, and M. Mauer, “Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions,” Diabetes, vol. 52, no. 4, pp. 1036–1040, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. I. H. De Boer, T. C. Rue, Y. N. Hall, P. J. Heagerty, N. S. Weiss, and J. Himmelfarb, “Temporal trends in the prevalence of diabetic kidney disease in the United States,” Journal of the American Medical Association, vol. 305, no. 24, pp. 2532–2539, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. Y.-M. Sun, Y. Su, J. Li, and L.-F. Wang, “Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy,” Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 359–361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. T. J. Lyons and A. Basu, “Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers,” Translational Research, vol. 159, no. 4, pp. 303–312, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. W. C. Cushman, G. W. Evans, R. P. Byington et al., “Effects of intensive blood-pressure control in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1575–1585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Sharma, N. Gillum, J. L. Boyd, and A. Schmid, “The RosR transcription factor is required for gene expression dynamics in response to extreme oxidative stress in a hypersaline-adapted archaeon,” BMC Genomics, vol. 13, no. 1, article 351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. B. Tripathi and D. Yadav, “Diabetic nephropathy: causes and managements,” Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, vol. 7, no. 1, pp. 57–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. E. J. Lewis, L. G. Hunsicker, R. P. Bain, and R. D. Rohde, “The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy,” The New England Journal of Medicine, vol. 329, no. 20, pp. 1456–1462, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. B. M. Brenner, M. E. Cooper, D. De Zeeuw et al., “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 345, no. 12, pp. 861–869, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. A. H. Barnett, S. C. Bain, P. Bouter et al., “Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 351, no. 19, pp. 1952–1961, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Manda, A.-I. Checherita, M. V. Comanescu, and M. E. Hinescu, “Redox signaling in diabetic nephropathy: hypertrophy versus death choices in mesangial cells and podocytes,” Mediators of Inflammation, vol. 2015, Article ID 604208, 13 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. B. K. Tiwari, K. B. Pandey, A. B. Abidi, and S. I. Rizvi, “Markers of oxidative stress during diabetes mellitus,” Journal of Biomarkers, vol. 2013, Article ID 378790, 8 pages, 2013. View at Publisher · View at Google Scholar
  40. M. Kalousová, J. Škrha, and T. Zima, “Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus,” Physiological Research, vol. 51, no. 6, pp. 597–604, 2002. View at Google Scholar · View at Scopus
  41. N. C. Chilelli, S. Burlina, and A. Lapolla, “AGEs, rather than hyperglycemia, are responsible formicrovascular complications in diabetes: a ‘glycoxidation-centric’ point of view,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 23, no. 10, pp. 913–919, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. E. J. Lee and J. H. Park, “Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble RAGE: potential biomarkers for diagnosis and therapeutic targets for human renal diseases,” Genomics & Informatics, vol. 11, no. 4, pp. 224–229, 2013. View at Publisher · View at Google Scholar
  43. J. M. Bohlender, S. Franke, G. Stein, and G. Wolf, “Advanced glycation end products and the kidney,” American Journal of Physiology—Renal Physiology, vol. 289, no. 4, pp. F645–F659, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Matsui, S. Yamagishi, S. Ueda et al., “Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-γ, activation,” Journal of International Medical Research, vol. 35, no. 4, pp. 482–489, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. M. T. Coughlan, D. R. Thorburn, S. A. Penfold et al., “Rage-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes,” Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 742–752, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Arici and J. Walls, “End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?” Kidney International, vol. 59, no. 2, pp. 407–414, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. L. B. Pupim, J. Himmelfarb, E. McMonagle, Y. Shyr, and T. A. Ikizler, “Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress,” Kidney International, vol. 65, no. 6, pp. 2371–2379, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Zalba, A. Fortuño, and J. Díez, “Oxidative stress and atherosclerosis in early chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2686–2690, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. A. A. Rodríguez-Albanes, E. Barranco-Hernández, C. A. Alonso-Rodríguez, and J. Soto-Matos, “Comportamiento de la peroxidación lipídica en insuficiencia renal crónica,” Revista Cubana de Investigaciones Biomédicas, vol. 22, no. 1, pp. 11–15, 2003. View at Google Scholar
  50. A. Fortuño, O. Beloqui, G. San José, M. U. Moreno, G. Zalba, and J. Díez, “Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease,” Kidney international. Supplement, no. 99, pp. S71–S75, 2005. View at Google Scholar · View at Scopus
  51. M. I. Yilmaz, M. Saglam, K. Caglar et al., “The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine,” American Journal of Kidney Diseases, vol. 47, no. 1, pp. 42–50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. Q. Lu, Y. Zhai, Q. Cheng et al., “The Akt-FoxO3a-manganese superoxide dismutase pathway is involved in the regulation of oxidative stress in diabetic nephropathy,” Experimental Physiology, vol. 98, no. 4, pp. 934–945, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. G. De Mattia, O. Laurenti, C. Bravi, A. Ghiselli, L. Iuliano, and F. Balsano, “Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients,” Metabolism, vol. 43, no. 8, pp. 965–968, 1994. View at Publisher · View at Google Scholar · View at Scopus
  54. E. N. Wardle, “Cellular oxidative processes in relation to renal disease,” American Journal of Nephrology, vol. 25, no. 1, pp. 13–22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Galle, “Oxidative stress in chronic renal failure,” Nephrology Dialysis Transplantation, vol. 16, no. 11, pp. 2135–2137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. S. P. Bagby, “Diabetic nephropathy and proximal tubule ROS: challenging our glomerulocentricity,” Kidney International, vol. 71, no. 12, pp. 1199–1202, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Fujita, H. Fujishima, S. Chida et al., “Reduction of renal superoxide dismutase in progressive diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 20, no. 6, pp. 1303–1313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. A. M. Samuni, W. DeGraff, M. C. Krishna, and J. B. Mitchell, “Cellular sites of H2O2-induced damage and their protection by nitroxides,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1525, no. 1-2, pp. 70–76, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Yamaguchi, K. Sano, K. Takakura et al., “Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial,” Stroke, vol. 29, no. 1, pp. 12–17, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. S. C. Gupta, S. Patchva, and B. B. Aggarwal, “Therapeutic roles of curcumin: lessons learned from clinical trials,” AAPS Journal, vol. 15, no. 1, pp. 195–218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Khajehdehi, M. Pakfetrat, K. Javidnia et al., “Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study,” Scandinavian Journal of Urology and Nephrology, vol. 45, no. 5, pp. 365–370, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, “Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 297, no. 8, pp. 842–857, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. H. K. Biesalski, T. Grune, J. Tinz, I. Zöllner, and J. B. Blumberg, “Reexamination of a meta-analysis of the effect of antioxidant supplementation on mortality and health in randomized trials,” Nutrients, vol. 2, no. 9, pp. 929–949, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Brien, H. Garcia, G. Garcia et al., “Epidemiologia de la insuficiencia renal crónica en Jalisco,” Boletin Colegio Jalisciense de Nefrologia, vol. 5, pp. 6–8, 2001. View at Google Scholar